The FDA has granted Cerus postmarket approval for its Intercept Blood System for Cryoprecipitation device that produces a blood component used to treat and control bleeding.

The system produces a frozen blood product prepared from blood plasma that is used for treating and controlling bleeding associated with fibrinogen deficiency and as a second-line treatment to control bleeding in several other conditions.

After thawing, the blood component produced by the device stays transfusion-ready at room temperature for up to five days, the company said.